Use of Infliximab for the Treatment of Pemphigus Vulgaris
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Pemphigus vulgaris (PV) is a rare skin disorder that causes blistering of the skin and mucous
membranes. Infliximab is a man-made antibody used to treat certain types of immune system
disorders, including rheumatoid arthritis and Crohn's disease. This study will determine if
infliximab given in combination with prednisone is a safe and effective treatment for adults
with PV.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)